http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Amgen (AMGN) Receives Positive CHMP Opinion on New Repatha Dose Delivery Option
-
New Repatha® (evolocumab) Dose Delivery Option Receives Positive CHMP Opinion
-
Amgen Announces Launch Of Blood Counts™ And Collaboration With StoryCorps To Record And Share Stories Of Those Impacted By Multiple Myeloma
-
Amgen (AMGN), Allergan (AGN) Announce Submission of ABP 215 MAA to EMA
-
Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab
-
Amgen To Present At The Citi 2016 Global Healthcare Conference
-
Amgen (AMGN), Cytokinetics (CYTK) Announce Publication of Significant Omecamtiv Mecarbil Phase 2 Data
-
The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure
-
The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function in Patients With Chronic Heart Failure
-
Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016
-
Arrowhead Research (ARWR) Reports Closing of License and Collaboration Agreement with Amgen (AMGN) on RNAi ARC-LPA Program
-
Amgen (AMGN) Announces Erenumab Phase 3 Met Primary Endpoint as Migraine Treatment
-
Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study
-
Amgen (AMGN) , Allergan (AGN) Submit Biosimilar BLA for ABP 215
-
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration
-
Amgen (AMGN) Announces Significant Data for Repatha in Regressing CAD-Related Atherosclerosis
-
Repatha® (Evolocumab) Regresses Atherosclerosis In Patients With Coronary Artery Disease
-
New 'Ten To Watch' List Highlights Top Amgen Scholars Poised To Impact The Future Of Science And Medicine
-
Amgen (AMGN), UCB Announce Significant Data from Phase 3 BRIDGE Study for Increasing BMD in Men With Osteoporosis
-
Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis
-
Amgen (AMGN) Reports EC Approval for Parsabiv to Treat sHPT in Adults with CKD
-
European Commission Approves Parsabiv™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis
-
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2016
-
Amgen (AMGN) Enters Multiple Myeloma Collaboration with Janssen
-
Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma
-
Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases
-
Amgen (AMGN) Receives FDA Approval for ENBREL sBLA as Expanded Indication
-
FDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis
-
Amgen To Present At The Credit Suisse 25th Annual Healthcare Conference
-
Amgen Appoints Lori Johnston As Senior Vice President, Human Resources
-
Amgen Highlights Repatha® (Evolocumab) GLAGOV Imaging Study Amongst Data To Be Presented At AHA Scientific Sessions 2016
-
Amgen Reports Third Quarter 2016 Financial Results
-
Trading Radar for 10/27: Alphabet (GOOG), Amazon (AMZN), Twitter (TWTR) Ford (F), Baidu.com (BIDU) Report
-
Amgen (AMGN) Makes Investment in Israel-Based eHealth Ventures
-
Amgen To Invest In Israel-Based eHealth Ventures
-
Amgen Announces Webcast Of 2016 Third Quarter Financial Results
-
Amgen (AMGN) Announces XGEVA vs. Zoledronic Acid Study Met Primary Endpoint; Secondary Endpoints Missed
-
Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients
-
Amgen Announces 2016 Fourth Quarter Dividend
-
Amgen (AMGN) Adds Former DuPont CEO Kullman as Director
-
Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors
-
Amgen (AMGN) Announces Additional Data from Vectibix in mCRC; Increased OS Observed
-
New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Le
-
Amgen (AMGN) Plans Presentation of New IMLYGIC Combo Data in Metastatic Colorectal Cancer at ESMO 2016
-
New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress
-
Amgen To Participate In Citi Biotech R&D Conference Call
-
Amgen (AMGN) Announces Publication of Positive BLINCYTO Phase 1/2 Single-Arm Trial in ALL; Says 39% Achieved Complete Remission
-
Study Results Published In Journal of Clinical Oncology Show BLINCYTO® (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapse
-
Amgen (AMGN), Arrowhead Pharma (ARWR) Enter Two Cardiovascular-Focused License, Collaboration Agreements
-
Amgen (AMGN), Arrowhead Pharmaceuticals (ARWR) Enter Collaborations on Two Cardiovascular Therapies
